Welcome To Where Deals Are Made
At the 26th Bio€quity Europe, top biopharma decision-makers and investors convene to shape the next era of biotech innovation. The new subscribers-only BioCentury Lounge elevates that experience by providing a private hub designed specifically for high-value conversations and discreet dealmaking.
- Intimate, distraction-free setting for closed-door meetings with key accounts, invited executives, and the prospects they choose to bring.
- A naturally self-selecting network of BioCentury customers, where peers operate at the same strategic altitude and can openly compare playbooks, wins, and challenges.
- A comfortable, hospitality-driven space with premium seating, refreshments, and charging so you can step away from the crowd without leaving the action.
Access is intentionally limited to maintain a high signal-to-noise ratio and ensure every interaction in the lounge is meaningful.
What BioCentury Subscribers & Event Sponsors Can Expect
A private command center for Bio€quity Europe, reserved for BioCentury subscribers who lead capital, BD, and corporate strategy decisions. Designed around the needs of VCs, CEOs, CFOs, CBOs, and senior BD leaders attending the 26th edition of Bio€quity Europe.
Host strategic 1:1s and small-group meetings with investors, partners, and senior executives away from the main conference traffic.
Use the lounge as a discreet setting to advance deal conversations that start in sessions or partnering.
Move seamlessly from formal Bio€quity Europe programming into off-the-record discussions that deepen relationships.
Meet peers tackling the defining challenges of the moment: how European biotech can accelerate to compete, and lead, amid new momentum from Asia and an unpredictable U.S. landscape.
Turn casual introductions into substantive conversations with C-level leaders, BD decision-makers, and experienced European operators attending in record numbers.
Compare playbooks on speed to the clinic, speed to early human data, and speed to de-risk assets. Surface collaboration opportunities that extend beyond the conference.
Step out of the bustle of the conference into a quieter, more controlled environment between sessions.
Refuel with refreshments, comfortable seating, and device charging so you stay sharp for high-stakes meetings.
Reset your strategy, catch up on notes, and prepare for your next set of sessions or 1:1s without leaving the venue.
Ready to Step Inside the Inner Circle?
The BioCentury Lounge is reserved for subscribers—but your access can start now. If you are not yet a subscriber and want to join this community of senior decision-makers, there are two simple next steps:
- Learn how BioCentury’s analysis and BCIQ can support your capital, BD, and strategy decisions year-round, and unlock access to subscriber-only experiences like the Lounge.
- Request a conversation with the BioCentury team to discuss your role, objectives, and which subscription option best fits your mandate.
Explore the Latest Analyses from BioCentury
Dive into our horizon-scanning analysis designed to help you make the most of your BioCentury Lounge experience.
EU investors sound the alarm
New coalition calls for increased capital inflows into EU biotech funds, improved capital markets, faster clinical trials
A confluence of falling equity and R&D investment in Europe, coupled with geopolitical instability, has convinced a group of blue-chip European VCs that now is the moment to mount a coordinated push to strengthen domestic biotech financing — and to press for policy and regulatory changes aimed at improving Europe’s competitiveness with the U.S. and China.
Resiliency in the face of volatility
BioCentury’s 2Q26 Public Markets Preview
Biotech markets look to maintain their outperformance heading into 2Q26 as geopolitical uncertainty reigns as the supreme overhang. Investors and bankers who spoke to BioCentury expect the primary drivers of the first quarter — strong follow-on and M&A markets — to continue to be the support for the sector in the near term.
Propagating innovation should be central to U.K. growth strategy — Daniel Mahony
One of U.K. biotech’s premier figures discusses dilemma and opportunities for the U.K. and Europe in capturing value from their innovations
WATCH NOW The U.K. is excellent at invention and science, and creating institutions to further innovation, but poor at capturing their economic value, says Daniel Mahony, a problem that various forces in the U.K. are now putting serious efforts into solving.
- BioCentury Analysis: Exclusive, deeply reported intelligence that senior teams use to make calls on pipelines, partnerships, policy, and pricing. It is designed for leaders who need to move first—and move confidently.
- BCIQ Business Intelligence Platform: A premium data and intelligence environment that unifies decades of BioCentury insight with deal, company, asset, and financing data, built for professionals whose job is to originate, evaluate, and close opportunities.
At the Summit, subscribers can use this intelligence edge to:
- Identify which counterparties are worth a meeting—and which are not.
- Enter each conversation pre-briefed on pipelines, partnerships, and deal history.
- Pressure-test ideas emerging from sessions in real time, so discussions in the lounge translate into concrete next steps.
The result is an event experience where networking is informed, targeted, and aligned with your mandate.